Meta-Analysis of Risk of Ventricular Arrhythmias and All-Cause Mortality in Patients With Chronic Total Occlusion of a Coronary Artery and/or Implantable Cardioverter-Defibrillator

被引:7
|
作者
Wang, Zhi-Quan [1 ]
Qiang, Hua [2 ]
Luo, Xiu [3 ]
Li, Wei [1 ]
Guo, Kai [1 ]
Li, Yi-Gang [1 ]
机构
[1] Shanghai Jiao Tong Univ, Xinhua Hosp, Sch Med, Dept Cardiol, Shanghai, Peoples R China
[2] Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Cardiovasc Med, Xian, Shaanxi, Peoples R China
[3] Tongji Univ, Tongji Hosp, Dept Hematol, Sch Med, Shanghai, Peoples R China
基金
中国国家自然科学基金;
关键词
RANDOMIZED CONTROLLED-TRIALS; ISCHEMIC-HEART-DISEASE; PRIMARY PREVENTION; NONISCHEMIC CARDIOMYOPATHY; IMPACT; RECIPIENTS; TACHYCARDIA; ALGORITHM; OUTCOMES;
D O I
10.1016/j.amjcard.2018.02.001
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Implantable cardioverter-defibrillator (ICD) has been increasingly used to prevent sudden death in patients with high risk of ventricular arrhythmias (VAs). Chronic total occlusion (CTO) is a severe condition of coronary artery disease. However, the prognostic impact of CTO in ICD recipients remains controversial. We systematically searched the PubMed, EMBASE, and Cochrane databases for documents published before October 1,2017 to identify studies that investigated the prognostic impact of CTO on VAs and all-cause mortality (ACM) in ICD recipients. The effect size was expressed by hazard ratio (HR) and 95% confidence interval (CI). Overall, 6 studies with 1,423 patients were included. We found that CTO independently predicted the occurrence of VAs in the global population (HR 1.77,95% CI 1.14 to 2.76, p = 0.01). Subgroup analysis revealed that CTO only predicted VAs in patients receiving ICD as secondary prevention (HR 1.96,95% CI 1.55 to 2.48, p <0.01). However, CTO was not associated with ACM in the global population (HR 1.51,95% CI 0.99 to 2.32, p = 0.06). Further subgroup analysis still showed no association between CTO and ACM in patients receiving ICD as primary prevention (HR 1.49, 95% CI 0.43 to 5.21, p = 0.53) or secondary prevention (HR 1.56, 95% CI 0.87 to 2.78, p = 0.13). In conclusion, CTO is an independent predictor of VAs in patients with secondary-prevention ICD, but not for ACM. Our study provided additional evidence for improving the risk stratification and management of VAs in ICD recipients. (C) 2018 Elsevier Inc. All rights reserved.
引用
收藏
页码:1149 / 1154
页数:6
相关论文
共 50 条
  • [21] The Impact of a Chronic Total Coronary Occlusion on Outcomes of Patients With an Implantable Cardioverter Defibrillator: Insights From the EXPLORE Trial
    van Veelen, Anna
    van Dongen, Ivo M.
    Elias, Joelle
    Henriques, Jose P. S.
    JOURNAL OF INVASIVE CARDIOLOGY, 2020, 32 (03) : E60 - E62
  • [22] Ventricular function and all-cause mortality in chronic kidney disease patients with angiographic coronary artery disease
    Wu, I-Wen
    Hung, Ming-Jui
    Chen, Yung-Chang
    Hsu, Heng-Jung
    Cherng, Wen-Jin
    Chang, Chee-Jen
    Wu, Mai-Szu
    JOURNAL OF NEPHROLOGY, 2010, 23 (02) : 181 - 188
  • [23] Effect of myocardial scar size on the risk of ventricular arrhythmias in patients with chronic total coronary occlusion
    Assaf, Amira
    van der Graaf, Marisa
    van Boven, Nick
    van Ettinger, Maarten J. B.
    Diletti, Roberto
    Hoogendijk, Mark G.
    Szili-Torok, Tamas
    Theuns, Dominic A. M. J.
    Yap, Sing-Chien
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2023, 390
  • [24] Elevated serum uric acid and risk of cardiovascular or all-cause mortality in people with suspected or definite coronary artery disease: A meta-analysis
    Wang, Ruijuan
    Song, Youxin
    Yan, Yaqi
    Ding, Zhenjiang
    ATHEROSCLEROSIS, 2016, 254 : 193 - 199
  • [25] Prognostic impact of chronic total coronary occlusion on long-term outcomes in implantable cardioverter-defibrillator recipients with ischaemic heart disease
    Nishikawa, Tatsuya
    Fujino, Masashi
    Nakajima, Ikutaro
    Asaumi, Yasuhide
    Kataoka, Yu
    Anzai, Toshihisa
    Kusano, Kengo
    Noguchi, Teruo
    Goto, Yoichi
    Nishimura, Kunihiro
    Miyamoto, Yoshihiro
    Kiso, Keisuke
    Yasuda, Satoshi
    EUROPACE, 2017, 19 (07): : 1153 - 1162
  • [26] A Comparative Study Between Amiodarone and Implantable Cardioverter-Defibrillator in Decreasing Mortality From Sudden Cardiac Death in High-Risk Patients: A Systematic Review and Meta-Analysis
    Zaki, Hany A.
    Shaban, Eman
    Bashir, Khalid
    Iftikhar, Haris
    Zahran, Adel
    Salem, Waleed
    Elmoheen, Amr
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (06)
  • [27] Do Implantable Cardioverter Defibrillators Reduce Mortality in Patients With Chronic Kidney Disease at All Stages? An Updated Meta-Analysis
    Fu, Linghua
    Zhou, Qiongqiong
    Zhu, Wengen
    Huang, Lin
    Ding, Ying
    Shen, Yang
    Hu, Jinzhu
    Hong, Kui
    INTERNATIONAL HEART JOURNAL, 2017, 58 (03) : 371 - 377
  • [28] Effect of metformin on all-cause and cardiovascular mortality in patients with coronary artery diseases: a systematic review and an updated meta-analysis
    Han, Yechen
    Xie, Hongzhi
    Liu, Yongtai
    Gao, Peng
    Yang, Xufei
    Shen, Zhujun
    CARDIOVASCULAR DIABETOLOGY, 2019, 18 (1)
  • [29] Impact of early ventricular tachycardia ablation in patients with an implantable cardioverter-defibrillator: An updated systematic review and meta-analysis of randomized controlled trials
    Prasitlumkum, Narut
    Navaravong, Leenhapong
    Desai, Aditya
    Desai, Darshi
    Cheungpasitporn, Wisit
    Rattanawong, Pattara
    Bunch, T. Jared
    Jongnarangsin, Krit
    Chokesuwattanaskul, Ronpichai
    HEART RHYTHM, 2022, 19 (12) : 2054 - 2061
  • [30] Peripheral Artery Disease Is an Independent Predictor of Mortality After Implantable Cardioverter-Defibrillator Implantation in Patients With Severe Left Ventricular Dysfunction
    Skeik, Nedaa
    McGriff, Deepa M.
    Katsiyiannis, William T.
    Sullivan, Timothy M.
    Mugglin, Andrew S.
    Retel, Linda M.
    Hauser, Robert G.
    ANGIOLOGY, 2014, 65 (06) : 507 - 511